BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23701126)

  • 21. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
    Teng CL; Hwang WL; Chen YJ; Chang KH; Cheng SB
    World J Surg Oncol; 2012 Feb; 10():41. PubMed ID: 22339891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
    Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
    Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.
    Duffy JP; Vardanian A; Benjamin E; Watson M; Farmer DG; Ghobrial RM; Lipshutz G; Yersiz H; Lu DS; Lassman C; Tong MJ; Hiatt JR; Busuttil RW
    Ann Surg; 2007 Sep; 246(3):502-9; discussion 509-11. PubMed ID: 17717454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
    Truesdale AE; Caldwell SH; Shah NL; Argo CK; Al-Osaimi AM; Schmitt TM; Northup PG
    Transpl Int; 2011 Oct; 24(10):991-8. PubMed ID: 21777298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed?
    Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Abdulkader I; Otero-Antón E; Tomé S; Varo-Pérez E
    Transplant Proc; 2012; 44(6):1565-7. PubMed ID: 22841215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation.
    Facciuto ME; Koneru B; Rocca JP; Wolf DC; Kim-Schluger L; Visintainer P; Klein KM; Chun H; Marvin M; Rozenblit G; Rodriguez-Davalos M; Sheiner PA
    Ann Surg Oncol; 2008 May; 15(5):1383-91. PubMed ID: 18320284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of Milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the Hungarian Liver Transplant Program.
    Nemes B; Gelley F; Piros L; Zádori G; Görög D; Fehérvári I; Kóbori L; Sárváry E; Nagy P; Kiss A; Doros A
    Transplant Proc; 2011 May; 43(4):1272-4. PubMed ID: 21620108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of hepatocellular carcinoma recurrence after liver transplantation.
    Valdivieso A; Bustamante J; Gastaca M; Uriarte JG; Ventoso A; Ruiz P; Fernandez JR; Pijoan I; Testillano M; Suarez MJ; Montejo M; Ortiz de Urbina J
    Transplant Proc; 2010 Mar; 42(2):660-2. PubMed ID: 20304217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.
    Lu DS; Yu NC; Raman SS; Lassman C; Tong MJ; Britten C; Durazo F; Saab S; Han S; Finn R; Hiatt JR; Busuttil RW
    Hepatology; 2005 May; 41(5):1130-7. PubMed ID: 15841454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China.
    Zhou J; Fan J; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Wang Z; Sun J; Xiao YS; He YF; Yang GH; Song K; Yuan Z; Wang YQ; Tang ZY
    Chin Med J (Engl); 2005 Apr; 118(8):654-9. PubMed ID: 15899120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate.
    Stockland AH; Walser EM; Paz-Fumagalli R; McKinney JM; May GR
    Cardiovasc Intervent Radiol; 2007; 30(5):888-93. PubMed ID: 17619218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
    Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
    Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation.
    Kiyici M; Yilmaz M; Akyildiz M; Arikan C; Aydin U; Sigirli D; Nart D; Yilmaz F; Ozacar T; Karasu Z; Kilic M
    Transplant Proc; 2008 Jun; 40(5):1511-7. PubMed ID: 18589140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
    Shin SY; Lee YJ
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):837-46. PubMed ID: 24075093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.
    Leung JY; Zhu AX; Gordon FD; Pratt DS; Mithoefer A; Garrigan K; Terella A; Hertl M; Cosimi AB; Chung RT
    Liver Transpl; 2004 Nov; 10(11):1343-54. PubMed ID: 15497158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
    Berretta M; Di Benedetto F; Dal Maso L; Cacopardo B; Nasti G; Facchini G; Bearz A; Spina M; Garlassi E; De Re V; Fiorica F; Lleshi A; Tirelli U
    Anticancer Drugs; 2013 Feb; 24(2):212-8. PubMed ID: 23197082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
    Martin RC; Bruenderman E; Cohn A; Piperdi B; Miksad R; Geschwind JF; Goldenberg A; Sanyal A; Zigmont E; Babajanyan S; Foreman P; Mantry P; McGuire B; Gholam P
    Am J Surg; 2017 Apr; 213(4):688-695. PubMed ID: 28318501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.
    Zavaglia C; De Carlis L; Alberti AB; Minola E; Belli LS; Slim AO; Airoldi A; Giacomoni A; Rondinara G; Tinelli C; Forti D; Pinzello G
    Am J Gastroenterol; 2005 Dec; 100(12):2708-16. PubMed ID: 16393224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.